ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO) Files An 8-K Results of Operations and Financial Condition

ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial Condition

On June 7, 2017, Organovo Holdings, Inc. (the Company) issued a
press release announcing financial results for its fourth quarter
and fiscal year ended March 31, 2017.A copy of the press release
is attached hereto as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K
(including Exhibit 99.1) is being furnished and shall not be
deemed filed for purposes of Section 18 of the Exchange Act of
1934 or otherwise subject to the liabilities of that Section and
shall not be incorporated by reference into any registration
statement or other document filed with the Securities and
Exchange Commission (the SEC).

Item 9.01 Financial Statements and Exhibits

(d)

Exhibit

No.

Exhibits

99.1

Press Release, dated June 7, 2017.


About ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO)

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.

An ad to help with our costs